Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Ischemic Preconditioning And Myocardial Infarction: An Update and Perspective. Drug discovery today. Disease mechanisms Gross, E. R., Gross, G. J. 2007; 4 (3): 165-174

Abstract

Myocardial infarction is the leading cause of mortality in Western societies with annual expenditures of $431.8 billion spent on coronary artery disease in man. Therapeutics to combat infarction from myocardial injury, based on studies of ischemic preconditioning (IPC), are currently in progress. Hence, this review provides an update on IPC, including general and molecular mechanisms responsible for IPC and the effects of IPC in models of aging or disease. A summary of therapeutics shown to possess efficacy in preclinical and clinical trials and future directions of studies regarding cardiac IPC are also discussed.

View details for DOI 10.1016/j.ddmec.2007.10.005

View details for PubMedID 18701939

View details for PubMedCentralID PMC2515553